(Q34254323)

English

Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review. (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

0 references

systematic review

1 reference

based on heuristic

inferred from title

Gerald Gartlehner

9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Megan Van Noord

object named as

Megan Van Noord

3

0 references

Richard A. Hansen

object named as

Richard A Hansen

5

0 references

Bradley N. Gaynes

object named as

Bradley N Gaynes

4

0 references

8

object named as

Kathleen N Lohr

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Kylie J Thaler

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Laura C Morgan

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Linda J Lux

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Erin E Krebs

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

publication date

2 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Depression and Anxiety

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

495-505

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Which factors influence psychiatrists' selection of antidepressants?

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the STAR*D clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Semi-automating the manual literature search for systematic reviews increases efficiency

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Current methods of the US Preventive Services Task Force: a review of the process

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

GRADE guidelines: 3. Rating the quality of evidence

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia.

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Effects of duloxetine on painful physical symptoms associated with depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Controlling for drug dose in systematic review and meta-analysis: a case study of the effect of antidepressant dose

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Predictors of alternative antidepressant agent initiation among U. S. veterans diagnosed with depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Treating the physical symptoms of depression with second-generation antidepressants: a systematic review and metaanalysis

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Predictors of an acute antidepressant response to fluoxetine and sertraline

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Ranking antidepressants

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

21 January 2018

Ranking antidepressants

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

7 January 2021

based on heuristic

inferred from DOI database lookup

Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors affecting prescribing of the newer antidepressants

1 reference

https://api.crossref.org/works/10.1002%2FDA.21951

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DA.21951

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

release_x7ykgusbhnaalpn7dj225nzxcu

1 reference

https://api.fatcat.wiki/v0/release/x7ykgusbhnaalpn7dj225nzxcu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34254323&oldid=1843392069"